Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

125.62 +0.67 (+0.54%)
Streaming Delayed Price Updated: 2:20 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
Economic Crossroads: How Key Indicators Are Steering the Stock Market Through Moderation and Policy Shifts
The financial markets are currently navigating a complex and often contradictory economic landscape, heavily influenced by a suite of critical indicators such as jobs data and the Purchasing Managers'... 
Via MarketMinute
Topics Artificial Intelligence Economy Immigration
Q3 Earnings Outperformers: Abbott Laboratories (NYSE:ABT) And The Rest Of The Medical Devices & Supplies - Diversified Stocks
Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Abbott Laboratories (NYSE:ABT) and its peers. 
Via StockStory
AI's Power Problem
AIs are hungry and growing more insatiable by the day. Will we be able to sustainably generate the power needed to feed the AI beast? 
Via The Motley Fool
Topics Artificial Intelligence Economy Energy
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat
Via MarketBeat
Dexcom Stock, Down 13%, Haunted By Its 'Surprisingly Cautious' Outlook
Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled. 
Via Investor's Business Daily
Should You Buy DexCom Stock Before Oct. 31?
The company hasn't had a great year. Is it about to turn things around? 
Via The Motley Fool
Topics Lawsuit
Recent Corporate Earnings Fuel Market Rally to Record Highs: AI and Rate Cut Hopes Drive Optimism
The third-quarter (Q3) 2025 earnings season has delivered a powerful jolt to global financial markets, propelling major U.S. indices to unprecedented record highs. A wave of surprisingly robust... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Is the Market Bullish or Bearish on Abbott Laboratories?
 
Via Benzinga
Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You?
Englander seems to have had several good reasons to aggressively buy shares of this big drugmaker. 
Via The Motley Fool
Topics Intellectual Property
Abbott Laboratories (NYSE:ABT): A Strong Dividend Stock for Reliable Income and Growth
Discover Abbott Laboratories (ABT), a top dividend stock with a 1.87% yield, 11% growth, and a strong financial profile for reliable income. 
Via Chartmill
Integer Holdings (ITGR) Shares Plunge 31.4% as Slower New Product Adoption and Revised Guidance Rock Investor Confidence
New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares... 
Via MarketMinute
Topics Earnings Supply Chain
EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards
Trinity Capital Inc. announced a financing agreement with Bobbie, an organic infant nutrition company, to boost production capacity and ensure wider distribution of its products. 
Via Benzinga
1 Safe-and-Steady Stock with Exciting Potential and 2 We Question
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
A Look Into Abbott Laboratories Inc's Price Over Earnings
 
Via Benzinga
Boston Scientific Soars: Q3 2025 Earnings Beat Ignites Medical Device Market
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
The 5 Most Interesting Analyst Questions From Abbott Laboratories’s Q3 Earnings Call
Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the market reacted negatively, with shares declining over 4%. Management pointed to... 
Via StockStory
Topics Earnings
U.S. Job Growth Stalls at 0.1%: Echoes of 2009 as Economy Navigates Fragile Labor Market
The U.S. economy is currently grappling with a significant deceleration in job growth, with proprietary data from investment giant Vanguard revealing a meager 0.1% growth rate for seven of the first... 
Via MarketMinute
Topics Artificial Intelligence Economy Immigration
Abbott Laboratories' October Price Plunge Is a Signal to Buy
Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend. 
Via MarketBeat
Analyst See Noise In Q3 P&L, Affirms Abbott's Medtech Strength
Abbott eyes 10% EPS growth in 2026 with CGM momentum, new nutrition contracts, and medical device launches driving global expansion. 
Via Benzinga
These Analysts Revise Their Forecasts On Abbott Following Q3 Results
 
Via Benzinga
Earnings Season Fuels Market Optimism Amidst Economic Headwinds
As the Q3 2025 earnings season unfolds, corporate America is delivering a powerful narrative of resilience and growth, significantly influencing overall stock market movements. Despite a complex... 
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Investors should be able to count on these stocks to deliver steady and growing income over the long term. 
Via The Motley Fool
ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30... 
Via StockStory
Topics World Trade
U.S. Stocks End Mixed Amidst Trade Tensions, Dovish Fed Hopes, and Robust Earnings
The U.S. stock market closed with a mixed performance recently, reflecting a complex and dynamic environment where investor sentiment is being pulled in multiple directions. As of October 15, 2025, a... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Why Abbott Laboratories (ABT) Stock Is Down Today
Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 3.5% in the afternoon session after the company reported third-quarter financial results that met, but did not... 
Via StockStory
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
 
Via Benzinga
Dividend Duo Delights Investors: Meta Platforms and Johnson & Johnson Shine in 2025
In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Wednesday's session: top gainers and losers in the S&P500 index
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Abbott Laboratories Remains In Favor With London Investment Manager, New Filing Shows
Via The Motley Fool
Topics Regulatory Compliance
Bank Earnings Lift Wall Street, Gold Hits $4,200: What's Moving Markets Wednesday?
Wall Street rose on Wednesday, with investor optimism lifted by strong bank and corporate earnings alongside growing expectations for further Federal Reserve rate cuts — keeping trade concerns... 
Via Benzinga
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.